Kura Oncology, Inc. (KURA) Downgraded to “Hold” at Zacks Investment Research
Zacks Investment Research cut shares of Kura Oncology, Inc. (NASDAQ:KURA) from a buy rating to a hold rating in a report released on Wednesday morning.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
KURA has been the topic of a number of other reports. ValuEngine cut Kura Oncology from a hold rating to a sell rating in a research note on Friday, September 1st. Oppenheimer Holdings, Inc. reiterated a buy rating and set a $16.00 target price on shares of Kura Oncology in a research note on Tuesday, July 4th. Leerink Swann reiterated an outperform rating and set a $18.00 target price (up from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Citigroup Inc. set a $13.00 target price on Kura Oncology and gave the stock a buy rating in a research note on Tuesday, August 8th. Finally, Cann reiterated a buy rating and set a $16.00 target price on shares of Kura Oncology in a research note on Monday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $14.15.
Kura Oncology (NASDAQ:KURA) opened at 6.95 on Wednesday. Kura Oncology has a 12-month low of $4.00 and a 12-month high of $12.10. The firm has a 50 day moving average of $7.99 and a 200 day moving average of $8.70. The firm’s market capitalization is $138.92 million.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.03. On average, analysts forecast that Kura Oncology will post ($1.60) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/07/kura-oncology-inc-kura-downgraded-to-hold-at-zacks-investment-research.html.
Several hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System purchased a new position in shares of Kura Oncology during the second quarter worth about $235,000. State Street Corp purchased a new position in shares of Kura Oncology during the second quarter worth about $1,394,000. OxFORD Asset Management LLP purchased a new position in shares of Kura Oncology during the second quarter worth about $217,000. Vanguard Group Inc. grew its holdings in shares of Kura Oncology by 13.0% during the second quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock worth $4,035,000 after purchasing an additional 50,033 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Kura Oncology by 939.3% during the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock worth $1,372,000 after purchasing an additional 133,293 shares in the last quarter. 39.07% of the stock is owned by institutional investors.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.